Systems and methods for analyzing extracellular vesicles using optical biosensors

Abstract

Various embodiments of systems and methods for analyzing extracellular vesicles (EVs) are disclosed, which have numerous innovative features. In one embodiment, a method for analyzing EVs includes binding EVs to an optical waveguide biosensor and phenotyping the bound EVs. Phenotyping can include binding a labeled ligand to the EVs and / or rupturing the EVs and analyzing their cargo. In another embodiment, a system for analyzing EVs includes EVs bound to an optical waveguide biosensor and a labeled ligand bound to the EVs. In another embodiment, a kit for analyzing EVs includes a microplate having wells containing an optical waveguide biosensor functionalized with a binding agent configured to bind to EVs, and at least one of (a) a labeled ligand configured to bind to extracellular vesicles or (b) a reagent configured to rupture extracellular vesicles.

Description

Related Applications

[0001] This application claims the benefit of priority under 35 U.S.C. §120 to U.S. Provisional Patent Application No. 62 / 773,753, filed November 30, 2018, the contents of which are relied upon and incorporated by reference in their entirety herein. [Technical field]

[0002] The present invention relates to systems and methods for analyzing extracellular vesicles using optical biosensors, and in particular to systems and methods for purifying, phenotyping and quantifying extracellular vesicles using optical biosensors. [Background technology]

[0003] Extracellular vesicles (EVs) are a heterogeneous population of membrane-enclosed vesicles. EVs are recognized as key elements in cell-cell communication and are involved in numerous biological and pathological processes. EVs have been linked to disease onset and progression, and based on this, EV analysis has been used in clinical settings. Due to the growing interest in EVs, methods to characterize EVs have been developed. These methods characterize various features of EVs, such as size distribution, counting, protein composition, and intravesicular contents.

[0004] Despite the development of these techniques, isolating and / or differentiating various EVs remains a major challenge. For example, traditional methods such as ultracentrifugation require highly specialized equipment that is not available in many laboratories, and extreme forces are applied to EVs that may damage them. Methods such as ultrafiltration, which utilize membranes with specific molecular weight cutoffs or pore sizes, may cause loss of EVs due to non-specific binding of EVs to the membrane material. Methods involving precipitation of EVs often result in results contaminated with proteins or other molecules. Methods using chromatographic columns to separate EVs based on affinity, size exclusion or ion exchange are laborious and time-consuming. Methods using microfluidic devices have a very low throughput. Summary of the Invention [Problem to be solved by the invention]

[0005] It would be desirable to develop characterization methods that are easier to use and / or yield better results. It is particularly desirable to develop techniques that allow for both the isolation and analysis of EVs in a microplate format. [Means for solving the problem]

[0006] Numerous methods have been disclosed for analyzing or evaluating extracellular vesicles (EVs) using optical biosensors, particularly optical waveguide biosensors. The methods can be used to purify EVs and / or analyze various properties of EVs. For example, the methods can be used to quantify and / or identify EVs in a sample medium, particularly EVs with one or more specific markers. The methods can be performed using a suitable EV analysis system. In one embodiment, the EV analysis system comprises an optical reader configured to receive and analyze a microplate with multiple wells, each well comprising an optical waveguide biosensor.

[0007] The methods and corresponding systems can be implemented in various ways to achieve one or more of the following potential advantages. One advantage is that EVs can be isolated, purified, and analyzed while still bound to the surface of the optical waveguide biosensor, making these processes simpler and easier. Another advantage is that EVs can be captured and phenotyped in a single step when they are bound to the surface of the optical waveguide biosensor using binding agents (e.g., antibodies) specific for known EV surface markers or receptors. Another advantage is that the EV analysis system can be performed using microplates, making it easier to adopt since microplate processing equipment is widespread in most laboratories. Another advantage is that EVs can be analyzed on a high-throughput basis.

[0008] One innovative aspect of the EV analysis method can be performed by binding EVs to the surface of an optical waveguide biosensor using a binding agent specific for a certain EV surface marker. The binding agent can be selected to capture only EVs that have the target marker. In this way, the process of binding EVs to the optical waveguide biosensor can be used to separate the EVs of interest from the rest of the sample medium, which contains other EVs that lack the target marker. This allows for label-free phenotyping of EVs directly from the sample.

[0009] Another innovative aspect of the EV analysis method can be performed by performing additional phenotyping analysis of the EVs after binding them to an optical waveguide biosensor, which may include quantification of the EVs, sorting and separation of the EVs based on the presence or absence of one or more additional markers, and / or analysis of the intravesicular contents of the EVs.

[0010] In one embodiment, the amount of EVs in a sample or bound to the surface of an optical waveguide biosensor can be determined by comparing the measurements of the sample to measurements of one or more samples containing known amounts of the same EVs or EVs with the same marker. For example, a standard curve can be generated using samples containing known amounts of a particular EV and compared to a curve generated by samples containing unknown amounts of the same EVs (or EVs with the same marker) to determine the amount of EVs in an unknown sample.

[0011] In another embodiment, the EVs can be further analyzed by binding one or more labeled ligands to additional markers or receptors present on the EVs. The ligands can be labeled with fluorescent, colorimetric and / or luminescent labels. The labeled ligands can be used to further characterize the type of EVs bound to the surface of the optical waveguide biosensor.

[0012] In another embodiment, the intravesicular contents of bound EVs can be analyzed. This can be done by rupturing the EVs with a suitable reagent and analyzing the contents, which may include proteins, DNA and / or RNA. In one embodiment, EVs can be ruptured with a lysis reagent such as TRIzol.

[0013] Please note that the term "phenotype" refers to the observable properties of EVs at any level, be it physical, morphological, biochemical or molecular.

[0014] The systems, methods and devices of the present disclosure each have several innovative aspects, no single one of which is solely responsible for the desirable attributes described. The Summary is presented to introduce in a simplified form a selection of concepts that are further described in the Detailed Description below. The Summary and Background are not intended to identify key concepts or essential aspects of the disclosed subject matter, and should not be used to constrain or limit the scope of the claims. For example, the claims should not be limited based on whether the recited subject matter includes any or all aspects described in the Summary and / or addresses any of the problems described in the Background. [Brief description of the drawings]

[0015] Other preferred embodiments are disclosed in the accompanying drawings. [Figure 1] FIG. 1 is a perspective view of a system for analyzing extracellular vesicles (EVs) according to an embodiment of the present disclosure. [Diagram 2] FIG. 2 is a cross-sectional view of an optical waveguide biosensor having a binding material on its upper surface according to an embodiment of the present disclosure. [Diagram 3] 3 is a cross-sectional view of the optical waveguide biosensor of FIG. 2 with EVs bound to a binding substance, according to an embodiment of the present disclosure. [Figure 4] 1 illustrates the operation of an optical resonant waveguide grating (RWG) biosensor according to an embodiment of the present disclosure. [Diagram 5]FIG. 1 illustrates one procedure for analyzing EVs according to an embodiment of the present disclosure. [Figure 6] FIG. 1 shows a cross-sectional view of an optical waveguide biosensor using a surface chemistry layer comprising poly(ethylene-alt-maleic anhydride) (EMA) to couple binding substances to EVs and the surface of the biosensor. [Figure 7] FIG. 1 shows a cross-sectional view of an optical waveguide biosensor using a surface chemistry layer containing streptavidin to attach binding substances to EVs and to the surface of the biosensor. [Figure 8] FIG. 11C shows a cross-sectional view of an optical waveguide biosensor in which bound EVs were further characterized by binding to a labeled ligand. [Figure 9] FIG. 2. Transverse cross-section of an optical waveguide biosensor in which bound EVs have been ruptured so that intravesicular contents can be analyzed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] EV Analysis System Referring to FIG. 1, a perspective view of a system 10 (alternatively referred to as an EV analysis system or EV assay system) for analyzing extracellular vesicles (EVs) is shown. The system 10 comprises a microplate 12, an optical reader 14 (alternatively referred to as an optical plate reader), and a laptop computer 16. The microplate 12 is configured to receive samples containing EVs. The optical reader 14 is configured to analyze the samples in the microplate 12. The computer 16 comprises software for operation of the instrument and data analysis. The computer 16 can be used to control the operation of the optical reader 14 and other associated laboratory equipment.

[0017] System 10 can be configured to have any suitable sample throughput. In some embodiments, system 10 can be considered a high throughput system (HTS) capable of measuring hundreds or even thousands of wells over an 8 hour period. For example, system 10 can be configured to measure at least 500 wells in 8 hours, at least 1000 wells in 8 hours, at least 2000 wells in 8 hours, at least 3000 wells in 8 hours, at least 4000 wells in 8 hours, or at least 5000 wells in 8 hours.

[0018] In high throughput embodiments, system 10 can be configured to be easily integrated with other equipment to facilitate rapid processing and analysis of large numbers of microplates 12. Additional equipment can include liquid handling systems, schedulers, etc. In these embodiments, many, if not all, of the operations of system 10 can be automated.

[0019] 1, optical reader 14 and computer 16 are shown as separate components. However, it should be understood that in other embodiments, optical reader 14 and computer 16 may be combined into a single unit. Many other modifications may be made to the configuration of optical reader 14 and computer 16.

[0020] Microplates A microplate 12 (alternatively referred to as a microwell plate or multiwell) is generally a flat plate with multiple wells 18 that function as small test tubes. Each well 18 includes an optical waveguide biosensor 20 integrated into the bottom of the well 18. The microplate 12 shown in FIG. 1 includes 384 wells 18.

[0021] However, it should be understood that the microplate 12 may include any suitable number of wells 18 arranged in any suitable manner. For example, the microplate 12 may include 6, 12, 24, 48, 96, 384, 768, or 1536 wells 18. Additionally, the wells 18 may be arranged in a variety of configurations, such as a 2:3 rectangular matrix.

[0022] Each well 18 can be configured to contain various amounts of liquid, ranging from a few nanoliters to several milliliters. As a general rule, as the number of wells 18 on a microplate 12 increases, the size of the wells 18 decreases. It should be understood that this is not a strict rule. There may be situations in which a microplate 12 has a few small wells 18 or a large number of large wells 18.

[0023] Wells 18 can also have any suitable shape and can be made from any suitable material. In some embodiments, wells 18 can be circular, square, polygonal, etc. In some embodiments, wells 18 can be made at least in part from polystyrene, polypropylene, polycarbonate, cycloolefins, metals, glass, ceramics, quartz, etc.

[0024] Microplate 12 can have any suitable configuration so long as it is capable of accommodating samples. In some embodiments, microplate 12 is constructed according to standards established by the Society for Biomolecular Screening (SBS), such as the SBS standard 384-well format.

[0025] Optical Waveguide Biosensor 2 and 3, a cross-sectional view of one embodiment of an optical waveguide biosensor 20 is shown. The optical waveguide biosensor 20 comprises a substrate layer 22, a waveguide layer 24 (alternatively referred to as a waveguide coating or waveguide thin film) on the substrate layer 22, and a surface chemistry layer 26 (alternatively referred to as a binding layer or binding surface) on the waveguide layer 24. The substrate layer 22 comprises an optical grating embedded in a substrate material such as glass. The waveguide layer 24 is a dielectric material having a high refractive index.

[0026] It should be understood that the optical waveguide biosensor 20 can be any suitable type of waveguide biosensor having any suitable configuration. For example, the optical waveguide biosensor 20 can be a single mode or multimode optical waveguide biosensor. The optical waveguide biosensor can also comprise any suitable type of waveguide, such as a resonant waveguide grating, a nanostructured optical grating, a planar waveguide, etc. The optical grating can be embedded in the substrate layer 22, the waveguide layer 24, or the interface of layers 22, 24. In one embodiment, the optical waveguide biosensor 20 is an optical resonant waveguide grating biosensor (RWG biosensor).

[0027] The surface chemistry layer 26 comprises a thin layer of surface chemistry (alternatively referred to as binding chemistry) that provides an active surface 30 on the top surface of the optical waveguide biosensor 20 for attachment and immobilization of EV-specific binding substances or targets 28. The surface chemistry provides a high binding capacity surface with low levels of non-specific binding. Note that the terms "bind" and "bound" are used to refer to a variety of binding methods including adsorption, covalent binding, non-covalent binding, chemisorption, etc.

[0028] Any suitable surface chemistry can be used to attach the binding agent 28 to the surface 30 of the optical waveguide biosensor 20. In one embodiment, the surface chemistry forms a covalent bond with a primary amine group on the binding agent 28. In another embodiment, the surface chemistry binds a biotinylated binding agent 28.

[0029] In one embodiment, surface chemistry layer 26 comprises poly(ethylene-alt-maleic anhydride) (EMA), which uses direct amine coupling to immobilize binding agent 28 by creating a covalent bond between amine groups on binding agent 28 and surface 30 of optical waveguide biosensor 20.

[0030] In another embodiment, surface chemistry layer 26 includes streptavidin that can be used to bind biotinylated molecules, such as binding substance 28 that is biotinylated (having biotin attached to binding substance 28), to surface 30. Streptavidin has a very high affinity bond to biotin that is as strong as a covalent bond.

[0031] In other embodiments, the surface chemistry layer 26 may include any of the surface chemistries described in the patent documents listed at the end of this specification.

[0032] The optical waveguide biosensor 20 is configured to detect a change in refractive index proximate the top surface 30 of the biosensor 20 that is indicative of a biochemical binding event, such as binding of EV32 to the top surface 30. The optical waveguide biosensor 20 can detect a change in refractive index in a region about 150-200 nm above the top surface 30. Below is a detailed description of one embodiment in which the optical waveguide biosensor 20 is an RWG biosensor.

[0033] With reference to FIG. 4, the operation of the optical RWG biosensor 20 is described. A light source 34 illuminates the bottom surface of each RWG biosensor 20 with broadband polarized light. Light of a particular wavelength where maximum incoupling efficiency is achieved (the resonant wavelength) couples into and propagates along the waveguide layer 24. This creates an electromagnetic field 36 at the interface between the top surface 30 and the solution that is evanescent in nature, i.e., decays exponentially from the top surface 30. The distance over which the electromagnetic field decays to 1 / e of its initial value (e is a numerical constant equal to 2.71828), known as the penetration, depends on the design of the particular RWG biosensor 20, but is typically between 150 and 200 nm.

[0034] The resonant light eventually escapes the waveguide layer 24 and is reflected back to a detector 38 (alternatively referred to as a detection head or detection unit) below the RWG biosensor 20. The wavelength of the reflected light is a function of the combined refractive index of the materials that make up the waveguide and the biomolecules within about 200 nm of the surface 30. When an analyte, such as EV32, binds to the surface 30, the local refractive index changes, which induces a shift in the wavelength of the light reflected from the RWG biosensor 20. The wavelength shift is proportional to the amount of analyte that binds to the surface 30.

[0035] The use of the RWG biosensor 20 can provide a number of advantages. One advantage of the RWG biosensor 20 compared to surface plasmon resonance (SPR) biosensors is that the RWG biosensor 20 can be illuminated with light at a nominally normal angle of incidence. This can be important when sampling multiple biosensors simultaneously.

[0036] Optical Reader The optical reader 14 includes a detector system 40 that uses integrated optical fibers to measure the shift in wavelength of the incident light. The detector system 40 includes a series of illumination heads 42 and detection heads 38 arranged in a linear fashion so that reflectance spectra can be collected simultaneously from each well 18 in the microplate 12. Each optical waveguide biosensor 20 can be addressed multiple times and scanned across the microplate 12 to address each column in turn. The wavelength of the incident light is measured and used to perform the analysis. The optical reader 14 may also include a temperature control unit that serves to reduce or minimize spurious shifts in the incident wavelength due to temperature fluctuations.

[0037] The sensing head 38 may include a spectrometer configured to measure the wavelength of the reflected light. The spectrometer may also be used to measure the peak power or resonance intensity to verify that the light source 34 is on the optical waveguide sensor 20.

[0038] The optical reader 14 can be used to measure the wavelength of reflected light under any of the following conditions (the conditions are explained in the left diagram of FIG. 5): The measurements can be used to generate sample and reference curves, which are also shown in FIG.

[0039] Reference wavelength 44 - buffer solution only and no binding substance 28 immobilized on the surface 30.

[0040] Reference wavelength 46 - unbound EV 32 in buffer solution and no binding material 28 immobilized on the surface 30.

[0041] Sample wavelength 48 - buffer solution only and binding substance 28 immobilized on surface 30.

[0042] Sample wavelength 50 - bound and unbound EV32 in buffer solution and binding substance 28 immobilized on surface 30.

[0043] Wavelength measurements can be used to obtain additional information about EV32. For example, the EV binding signal 52 can be determined by subtracting the reference wavelength 46 from the sample wavelength 50. In some embodiments, a standard wavelength can be measured and a corresponding curve can be generated for samples containing known amounts of EV32. The standard wavelength can be compared to the sample wavelength 50 to determine the amount of EV32 in a given sample.

[0044] EV analysis method 6 and 7, there are shown cross-sectional views of an optical waveguide biosensor 20. The optical waveguide biosensor 20 of FIG. 6 includes poly(ethylene-alt-maleic anhydride) as the surface chemistry layer 26, and the biosensor 20 of FIG. 7 includes streptavidin as the surface chemistry layer 26.

[0045] The surface chemistry layer 26 binds the binding substance 28 to the surface 30 of the optical waveguide biosensor 20. In some embodiments, the microplate 12 may be provided with the surface chemistry layer 26 and / or binding substance 28 already disposed thereon. In this situation, the microplate 12 is ready for use upon receipt. In other embodiments, the microplate 12 may be provided without the surface chemistry layer 26 and / or binding substance 28 disposed thereon. In this situation, the user must apply the desired surface chemistry layer 26 and / or binding substance 28 to the surface 30.

[0046] binding substance The binding agent 28 can be any suitable agent capable of binding to a marker or receptor 54 on EV32. Examples of suitable agents include proteins, antibodies, antibody fragments, etc. In some embodiments, the binding agent 28 can be an antibody or antibody fragment specific for a surface marker on EV32.

[0047] The term "antibody" refers to an immunoglobulin molecule that specifically binds to an antigen. An antibody may be an intact immunoglobulin derived from natural or recombinant sources, or an immunoreactive portion of an intact immunoglobulin. An antibody may be a tetramer of immunoglobulin molecules. The tetramer may be naturally occurring or reconstituted from single chain antibodies or antibody fragments.

[0048] Antibodies also include dimers, which may be naturally occurring or comprised of single chain antibodies or antibody fragments. Antibodies include, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab') 2 , as well as single chain antibodies (scFv), humanized antibodies and human antibodies.

[0049] The term "antibody fragment" refers to a portion of an intact antibody and refers to the antigen-determining variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab') 2Antibody fragments include, but are not limited to, Fv fragments, linear antibodies, scFv antibodies, single domain antibodies such as camelid antibodies composed of either a VL or VH domain that exhibits sufficient affinity for a target, and multispecific antibodies formed from antibody fragments. Antibody fragments also include human or humanized antibodies, or portions of human or humanized antibodies.

[0050] The term "fragment" refers to a portion of a protein or nucleic acid molecule (e.g., at least 10, 25, 50, 100, 125, 150, 200, 250, 300, 350, 400, or 500 amino acids or nucleic acids) that is substantially identical to a reference protein or nucleic acid and retains the biological activity of the reference.

[0051] The binding agent 28 can be selected to bind to a specific membrane-bound receptor 54 on the EV32. The EV32 can contain a variety of different surface molecules that can bind to various EV-specific binding agents 28.

[0052] Extracellular vesicles The term "extracellular vesicles" (EVs) refers to small membrane-enclosed structures that are released into the extracellular space by various cell types, such as endothelial cells, epithelial cells, platelets, and additionally tumor cells. Typically, at least a portion of the membrane of EV32 is obtained directly from a cell (also known as a donor cell). EV32 can arise from a cell by membrane eversion, exocytosis, shedding, blebbing and / or budding. Depending on the mode of production (e.g. membrane eversion, exocytosis, shedding or budding), EV32 can display different surface / lipid properties.

[0053] EV32 may contain heterogeneous compositions of proteins, lipids, nucleic acids or other biomolecules inside the membrane of EV32. The molecular contents of EV32 may represent its cell of origin, including surface and cytoplasmic proteins, messenger RNA, and microRNA. EV32 can transport these molecules to various target cells and locations within the body or biological system. The genetic information within EV32 can be transferred by fusing with the membrane of a recipient cell and releasing the genetic information into the cell.

[0054] EV32 may be of various sizes. For example, EV32 may have a diameter (or maximum dimension if the structure is not spherical) of 10-5000 nm, 20-3000 nm or 30-2000 nm. EV32 may have a diameter (or maximum dimension if the structure is not spherical) of at least 10 nm, at least 20 nm or at least 30 nm. EV32 may have a diameter (or maximum dimension if the structure is not spherical) of 5000 nm or less, 3000 nm or less or 2000 nm or less.

[0055] EV32 can be isolated from a variety of biological sources, including mammals such as mice, rats, guinea pigs, rabbits, dogs, cats, cows, horses, goats, sheep, primates, or humans. EV32 can be isolated from bodily fluids such as serum, plasma, whole blood, urine, saliva, milk, tears, sweat, synovial fluid, cerebrospinal fluid, semen, vaginal fluid, peritoneal fluid, and amniotic fluid. EV32 can also be isolated from experimental samples such as media taken from cultured cells ("conditioned media", cell culture media, and cell culture media).

[0056] EV32 can also be isolated from tissue samples such as surgical samples, biopsy samples, and cultured cells. When isolating EV32 from tissue sources, it may be beneficial to homogenize the tissue to obtain a single cell suspension, followed by lysing the cells to release EV32. When isolating EV32 from tissue samples, homogenization and lysis procedures that do not cause destruction of EV32 should be used.

[0057] EV32 can be classified into numerous subpopulations based on specific characteristics such as size, biogenesis, cellular origin, protein composition, biological functions, etc. EV32 can be broadly divided into three main subtypes according to their cellular origin: exosomes, microvesicles (MVs) (also called shed vesicles), and apoptotic bodies, as shown in the table below.

[0058] [Table 1]

[0059] Exosomes are typically of endocytic origin, forming vesicles within endosomal compartments by invagination of the endosomal membrane generating multivesicular bodies (MVBs). Exosomes are released into the extracellular space upon fusion of the MVBs with the plasma membrane. Exosomes typically range in size from 30 to 100 nm and have a density of 1.13 to 1.19 g / ml.

[0060] Due to the biogenesis of exosomes, the orientation of exosomal membrane proteins is similar to the plasma membrane. In addition to the similar orientation, the lipid composition of the exosomal membrane is similar to the plasma membrane and contains cholesterol, ceramide and phosphatidylserine (PS) along with several protein markers that can be used to identify exosomes. These include proteins involved in the MVB formation machinery (e.g. Alix and Tsg101), proteins from the membrane and fusion machinery (e.g. GTPases, annexins and flotillins), and tetraspanins (CD9, CD63 and CD81). Exosomes may also display sugar groups on their surface.

[0061] Although various markers may not be universally present on all exosomes, they are present on the majority of exosomes and are therefore generally accepted as exosome markers. In addition to exosomal proteins, exosomes often exhibit molecular compositions that reflect the molecular signature of the parent cell. In some cases, the molecular content of exosomes may not result from chance sampling of molecules from the parent cell, but rather may result from the ability to load specific molecules onto exosomes. Exosomes may also contain significant amounts of RNA, including miRNA, non-coding RNA, mRNA, miRNA, etc.

[0062] Microvesicles are typically formed by outward budding of the plasma membrane releasing MVs directly into the extracellular space. Some MVs display PS on the outer leaflet of the membrane, and this feature can be used to isolate and identify MVs in biological samples. MVs may contain markers such as CD40 ligand, adenosine diphosphate ribosylation factor 6, and certain integrins and selectins. The intravesicular contents of MVs may include membrane and cytoplasmic proteins, mRNA, miRNA, etc. MVs may range in size from 50 to 1000 nm.

[0063] Apoptotic bodies are typically released when cells undergo apoptosis and are formed by plasma membrane blebbing that releases the apoptotic body directly into the extracellular space. Similar to other subtypes of EV32, apoptotic bodies display PS on the outer leaflet of the lipid bilayer. In addition, apoptotic bodies display thrombospondin and the complement component C3b, which can be used to identify apoptotic bodies. Furthermore, apoptotic bodies can be distinguished from other EV subtypes by containing organelles, DNA fragments and histones as part of the intravesicular cargo in addition to proteins and other molecules derived from the parent cell cytosol. Apoptotic bodies can range in size from 500 to 4000 nm and have a density of 1.16 to 1.28 g / ml.

[0064] The terms "microRNA", "miRNA" or "miR" typically refer to RNA that functions to post-transcriptionally regulate gene expression by binding to complementary sequences in the 3' untranslated region (3'UTR) of target messenger RNA (mRNA) transcripts, usually resulting in gene silencing. miRNAs are typically small regulatory RNA molecules, e.g., 21 or 22 nucleotides in length (up to 100 nucleotides in length or up to 50 nucleotides in length). The terms "microRNA", "miRNA" and "miR" are used interchangeably.

[0065] EV isolation EV32 can be isolated from a sample using the following procedure. If the binding substance 28 is not already attached to the microplate 12, the first step is to attach the binding substance 28. This can be done by adding an immobilization buffer solution containing the binding substance 28 to each of the wells 18 and incubating the microplate 12 until the binding substance 28 is immobilized on the surface chemistry layer 26.

[0066] The immobilization buffer solution is removed and replaced with a blocking buffer solution which inactivates the remaining immobilization sites on the surface chemistry layer 26. The blocking buffer solution is removed and the wells 18 are rinsed. At this point, the microplate 12 is ready to receive and analyze samples containing EV32.

[0067] A sample containing EV32 is placed in the well 18. The EV32 binds to a binding substance 28 that is bound to the surface 30 of the biosensor 20 in the manner shown in Figures 6 and 7. The remainder of the sample is washed out of the well 18, leaving only the bound EV32 on the microplate 12. In this way, the bound EV32 can be isolated and phenotyped based on the presence of a marker capable of binding to the binding substance 28, and all this can be done in a single step.

[0068] Quantification of EVs The amount of EV32 in a given sample can be determined by measuring the wavelength of the sample and comparing it to one or more standard wavelengths obtained from samples containing known concentrations of the same EV32. The procedure for measuring the standard wavelengths of samples containing known concentrations of EV32 and comparing them to the wavelengths measured for samples containing unknown concentrations of EV32 is described above.

[0069] Secondary phenotyping of EVs 8, the bound EV32 can be further separated and sorted using one or more labeled or tagged ligands 56 configured to bind to another marker or receptor 60 on the EV32. The ligand 56 can include any suitable type of label or tag 58. For example, the ligand 56 can include a fluorescent label, a colorimetric label, or a luminescent label.

[0070] Ligand 56 can be any suitable protein, compound, molecule, etc. capable of binding to a specific marker on EV32. In some embodiments, ligand 56 can be any of the binding agents 28 or antibodies described above in connection with EV32. In some embodiments, two, three, four or more different ligands 56, each with a different label 58, can be used to further separate and classify EV32.

[0071] The number of EV32 bound to a given ligand 56 can be quantified using the same techniques as described above in relation to bound EV32, i.e. standard wavelength measurements can be obtained using samples containing known amounts of the relevant EV32 and compared to the wavelength measurements of the labeled EV32.

[0072] Intravesicular contents of EVs 9, the intravesicular contents of bound EV32 can be analyzed using the following procedure. A reagent 62 can be added to wells 18 to rupture or lyse the EV32 and expose their contents for further analysis. Any suitable reagent 62 can be used to rupture the EV32. In some embodiments, the reagent 62 is a lysis reagent, such as TRIzol lysis reagent.

[0073] The vesicular contents of EV32 can include proteins, DNA, RNA (microRNA), etc. These molecules can be extracted by removing them into a separate container and completing a standard phase separation extraction protocol. These molecules can be analyzed to diagnose disease, determine disease prognosis, etc.

[0074] A method to analyze EV32 could provide a number of advantages. One advantage is that this technique can be used to isolate, quantify and phenotype EV32 directly from complex biological samples such as body fluids, e.g. serum, cell culture medium, urine, etc., without intermediate purification steps.

[0075] EV Analysis Kit A kit for analyzing EV32 may include any of the materials and components described above. In one embodiment, the kit may include a microplate 12 and at least one of the labeled ligand 56 or the reagent 62. In other embodiments, the kit may include packaging configured to house the components of the kit together or to indicate that a component is part of the kit. EXAMPLES

[0076] The following examples are presented to further illustrate the disclosed subject matter and should not be used to constrain or limit the scope of the claims in any way.

[0077] Example 1 In this example, the amount of extracellular vesicles (EVs) with specific biomarkers in a sample is analyzed using Corning's Epic system, a label-free high-throughput screening system. The system comprises a biosensor microplate with 384 sample wells. Each sample well has an optical resonant waveguide grating biosensor (RWG biosensor) located on the bottom surface. The RWG biosensor comprises a nanometer-scale optical grating embedded in a substrate and a high-index waveguide layer or coating applied to the substrate. The system also comprises an optical reader that illuminates the RWG biosensor with a broadband light source.

[0078] Light at the resonant wavelength is coupled into the waveguide layer and propagates along it. The evanescent field generated by the resonant coupling of light penetrates approximately 150 nm into the layer above the RWG biosensor probing the local refractive index. The resonant wavelength is detected by a CMOS camera after being outcoupled from the RWG biosensor. The resonant wavelength of the light shifts due to the change in the refractive index of the sensing zone caused by EVs binding to the RWG biosensor.

[0079] The RWG biosensor comprises a surface chemistry layer on the top surface, which comprises polyethylene-maleic anhydride (EMA), which immobilizes antibodies on the RWG biosensor by creating covalent bonds between amine groups on the antibodies and the top surface.

[0080] An array of EV-specific antibodies is created in the wells of a microplate as follows: Antibodies are diluted in a buffer solution and added to the majority of the wells in the microplate. A control buffer solution is added to the remaining wells to form buffer-only control wells that are used to quantify antibody immobilization levels. The microplate is incubated to promote immobilization of the antibodies to the top surface of the RWG biosensor. The buffer solution is removed and replaced with a blocking buffer solution that inactivates the remaining immobilization sites. The blocking buffer is removed and the wells are rinsed.

[0081] EVs are bound to the RWG biosensor as follows: Fresh cell culture medium without serum is added to the wells. The microplate is placed in an optical reader and equilibrated for approximately 2 hours to allow the sensor to stabilize. The resonant wavelength of the wells is measured to generate a baseline. Cell culture medium containing a known amount of EVs with a specific marker and cell culture medium containing an unknown amount of the same EVs are added to the antibody-immobilized wells, leaving some wells without EVs as controls. The microplate is incubated for approximately 1 hour to allow EVs to bind to the antibody. The resonant wavelength of the wells is measured.

[0082] A standard curve is constructed using cell culture medium containing known amounts of EVs and control measurements. The amount of EVs bearing the marker in unknown cell culture medium is determined by comparing the standard curve with the curve constructed using cell culture medium containing unknown amounts of EVs.

[0083] Example 2 In this example, additional phenotypic information about EVs is obtained using Corning's Epic system and labeled antibodies. EVs are bound to an RWG biosensor and analyzed as described in Example 1. After measuring the resonant wavelength of the wells containing bound EVs, the medium is removed from the wells and a buffer solution containing a fluorescently labeled antibody is added (this example can also be repeated with colorimetric or luminescent labels). The labeled antibody binds to a second marker or epitope of certain EVs. The labeled antibody provides additional phenotypic information about the EVs by identifying other surface markers, including those that may be markers for certain diseases. The amount of bound EVs bearing the second marker is determined by generating a standard curve as described in Example 1 and comparing it to a curve generated using cell culture medium containing an unknown amount of EVs bearing the same marker.

[0084] Example 3 In this example, additional phenotypic information is obtained by examining the intravesicular contents of EVs. EVs are bound to an RWG biosensor and analyzed as described in Example 1 or Example 2. EVs are lysed by adding TRIzol reagent (a monophasic solution of phenol and guanidine isothiocyanate) to the bound EVs in the wells. This releases the intravesicular contents of the EVs, including proteins, DNA, RNA (e.g., miRNA), etc. The contents of the wells are removed to a separate container and separated following standard phase separation extraction protocols. The miRNA is analyzed for disease diagnosis and / or for determining disease prognosis.

[0085] Exemplary Implementations Below are descriptions of various embodiments of the disclosed subject matter. Each embodiment may include one or more of the various features, characteristics, or advantages of the disclosed subject matter. The embodiments are intended to illustrate some aspects of the disclosed subject matter and should not be considered a comprehensive or exhaustive description of all possible embodiments.

[0086] P1. A method comprising placing a sample containing extracellular vesicles on an optical waveguide biosensor, binding the extracellular vesicles to the optical waveguide biosensor, detecting the extracellular vesicles bound to the optical waveguide biosensor, and analyzing a characteristic of the extracellular vesicles bound to the optical waveguide biosensor.

[0087] P2. The method of paragraph P1, wherein the characteristic of the extracellular vesicles comprises the number of extracellular vesicles in the sample.

[0088] P3. The method of paragraphs P1 or P2, wherein the characteristic of the extracellular vesicles comprises a size of the extracellular vesicles in the sample.

[0089] P4. The method of any one of paragraphs P1 to P3, wherein the characteristic of the extracellular vesicles comprises the type of extracellular vesicles in the sample.

[0090] P5. The method of any one of paragraphs P1 to P4, wherein analyzing the properties of the extracellular vesicles comprises binding a ligand to the extracellular vesicles.

[0091] P6. The method of paragraph P5, wherein the ligand comprises a first ligand that binds to a first marker on the extracellular vesicle and a second ligand that binds to a second marker on the extracellular vesicle.

[0092] P7. The method of paragraphs P5 or P6, comprising binding a ligand to the extracellular vesicles while binding the extracellular vesicles to an optical waveguide biosensor.

[0093] P8. The method of any one of paragraphs P5 to P7, wherein the ligand comprises a label.

[0094] P9. The method of paragraph P8, wherein the label is a fluorescent label.

[0095] P10. The method of paragraphs P8 or P9, wherein the label is a colorimetric label.

[0096] P11. The method of any one of paragraphs P8 to P10, wherein the label is a luminescent label.

[0097] P12. The method of any one of paragraphs P1 to P11, wherein analyzing the characteristics of the extracellular vesicles comprises analyzing the intravesicular contents of the extracellular vesicles.

[0098] P13. The method of paragraph P12, wherein analyzing the intravesicular contents of the extracellular vesicles includes analyzing proteins, RNA and / or DNA in the intravesicular contents.

[0099] P14. The method of paragraphs P12 or P13, wherein analyzing the intravesicular contents of the extracellular vesicles comprises analyzing the composition of the intravesicular contents.

[0100] P15. The method of any one of paragraphs P12 to P14, wherein analyzing the intravesicular contents of the extracellular vesicles comprises rupturing the extracellular vesicles.

[0101] P16. The method of paragraph P15, comprising rupturing the extracellular vesicles while binding the extracellular vesicles to an optical waveguide biosensor.

[0102] P17. The method of any one of paragraphs P12 to P16, wherein analyzing the intravesicular contents of the extracellular vesicles comprises lysing the extracellular vesicles.

[0103] P18. The method of paragraph P17, comprising lysing the extracellular vesicles while binding the extracellular vesicles to an optical waveguide biosensor.

[0104] P19. The method of any one of paragraphs P1 to P18, wherein the sample is an unpurified biological sample.

[0105] P20. The method of any one of paragraphs P1 to P19, wherein the sample is an unpurified bodily fluid.

[0106] P21. The method of any one of paragraphs P1 to P20, wherein detecting extracellular vesicles comprises illuminating an optical waveguide biosensor and detecting a change in the resonant wavelength of light reflected from the optical waveguide biosensor.

[0107] P22. The method of any one of paragraphs P1 to P21, comprising binding a binding substance to an optical waveguide biosensor and binding extracellular vesicles to the binding substance.

[0108] P23. The method of paragraph P22, wherein the binding agent comprises an antibody.

[0109] P24. The method of any one of paragraphs P1 to P23, wherein the optical waveguide biosensor is an optical resonant waveguide grating biosensor.

[0110] P25. A system for analyzing extracellular vesicles, comprising an optical waveguide biosensor, extracellular vesicles bound to the optical waveguide biosensor, and a ligand comprising a label bound to the extracellular vesicles.

[0111] P26. The system of paragraph P25, wherein the ligand comprises an antibody configured to bind to a marker on the extracellular vesicle.

[0112] P27. The system of paragraphs P25 or P26, wherein the ligand is a first ligand, the label is a first label, and the system comprises a second ligand bound to the extracellular vesicle, the second ligand comprising a second label.

[0113] P28. The system of paragraph P27, wherein the first ligand is configured to bind to one marker on the extracellular vesicle and the second ligand is configured to bind to another marker on the extracellular vesicle.

[0114] P29. The system of any one of paragraphs P25 to P28, wherein the label is a fluorescent label.

[0115] P30. The system of any one of paragraphs P25 to P29, wherein the label is a colorimetric label.

[0116] P31. The system of any one of paragraphs P25 to P30, wherein the sign is a luminescent sign.

[0117] P32. The system of any one of paragraphs P25 to P31, comprising an optical reader configured to detect extracellular vesicles bound to an optical waveguide biosensor.

[0118] P33. The system of paragraph P32, wherein the optical reader comprises a light source configured to illuminate the optical waveguide biosensor.

[0119] P34. The system of paragraph P33, wherein the light source is a broadband light source.

[0120] P35. The system of any one of paragraphs P25 to P34, comprising an optical reader configured to illuminate the optical waveguide biosensor and detect a change in resonant wavelength of light reflected from the optical waveguide biosensor.

[0121] P36. The system of any one of paragraphs P25 to P35, wherein the optical waveguide biosensor is an optical resonant waveguide grating biosensor.

[0122] P37. The system of any one of paragraphs P25 to P36, wherein the extracellular vesicle is an exosome.

[0123] P38. The system of any one of paragraphs P25 to P37, wherein the extracellular vesicles are microvesicles.

[0124] P39. The system of any one of paragraphs P25 to P38, wherein the extracellular vesicles are apoptotic bodies.

[0125] P40. The system of any one of paragraphs P25 to P39, comprising a plurality of optical waveguide biosensors and a microplate including a plurality of wells, each well comprising at least one of the plurality of optical waveguide biosensors.

[0126] P41. The system of paragraph P40, wherein the microplate comprises at least 24 wells.

[0127] P42. The system of paragraph P40, wherein the microplate comprises at least 96 wells.

[0128] P43. The system of paragraph P40, wherein the microplate comprises at least 384 wells.

[0129] P44. A system for analyzing extracellular vesicles, comprising: a microplate including a plurality of wells; an optical waveguide biosensor disposed in each of the plurality of wells; and a sample disposed in each of the plurality of wells, each of the samples comprising intravesicular contents of ruptured extracellular vesicles bound to the optical waveguide biosensor.

[0130] P45. The system of paragraph P44, wherein each sample comprises intravesicular contents of lysed extracellular vesicles bound to an optical waveguide biosensor.

[0131] P46. The system of paragraphs P44 or P45, wherein the sample comprises a lysis reagent.

[0132] P47. The system of any one of paragraphs P44 to P46, wherein the intravesicular contents of the ruptured extracellular vesicles comprise protein, RNA and / or DNA.

[0133] P48. The system of any one of paragraphs P44 to P47, comprising an optical reader configured to detect extracellular vesicles bound to an optical waveguide biosensor.

[0134] P49. The system of paragraph P48, wherein the optical reader comprises a light source configured to illuminate the optical waveguide biosensor.

[0135] P50. The system of paragraph P49, wherein the light source is a broadband light source.

[0136] P51. The system of any one of paragraphs P44 to P50, comprising an optical reader configured to illuminate an optical waveguide biosensor and detect a change in resonant wavelength of light reflected from the optical waveguide biosensor.

[0137] P52. The system of any one of paragraphs P44 to P51, wherein the optical waveguide biosensor is an optical resonant waveguide grating biosensor.

[0138] P53. The system of any one of paragraphs P44 to P52, wherein the ruptured extracellular vesicles are exosomes.

[0139] P54. The system of any one of paragraphs P44 to P53, wherein the ruptured extracellular vesicles are microvesicles.

[0140] P55. The system of any one of paragraphs P44 to P54, wherein the ruptured extracellular vesicles are apoptotic bodies.

[0141] P56. The system of any one of paragraphs P44 to P55, wherein the microplate comprises at least 24 wells.

[0142] P57. The system of any one of paragraphs P44 to P56, wherein the microplate comprises at least 96 wells.

[0143] P58. The system of any one of paragraphs P44 to P57, wherein the microplate comprises at least 384 wells.

[0144] P59. A kit for analyzing extracellular vesicles, comprising: a microplate including a plurality of wells; an optical waveguide biosensor disposed in each of the plurality of wells; a binding substance coupled to each of the optical waveguide biosensors and configured to bind to extracellular vesicles; and at least one of (a) a ligand including a label and configured to bind to the extracellular vesicles, or (b) a reagent configured to rupture the extracellular vesicles.

[0145] P60. The kit of paragraph P59, wherein the binding substance attached to each of the optical waveguide biosensors comprises an antibody configured to bind to a marker on an extracellular vesicle.

[0146] P61. The kit of paragraphs P59 or P60, wherein the ligand comprises a first ligand configured to bind to a first marker on the extracellular vesicle and a second ligand configured to bind to a second marker on the extracellular vesicle.

[0147] P62. The kit of any one of paragraphs P59 to P61, wherein the reagent comprises a lysis reagent configured to lyse extracellular vesicles.

[0148] P63. The kit of any one of paragraphs P59 to P62, comprising both (a) and (b).

[0149] P64. The kit of any one of paragraphs P59 to P63, comprising an optical reader configured to detect extracellular vesicles bound to an optical waveguide biosensor.

[0150] P65. A kit according to any one of paragraphs P59 to P64, comprising a package showing the microplate and at least one of (a) or (b) as a unit.

[0151] P66. The kit of any one of paragraphs P59 to P65, comprising a package housing the microplate and at least one of (a) or (b) together as a unit.

[0152] P67. The kit of any one of paragraphs P59 to P66, wherein the optical waveguide biosensor is an optical resonant waveguide grating biosensor.

[0153] P68. The kit of any one of paragraphs P59 to P67, wherein the extracellular vesicles are exosomes.

[0154] P69. The kit of any one of paragraphs P59 to P68, wherein the extracellular vesicles are microvesicles.

[0155] P70. The kit of any one of paragraphs P59 to P69, wherein the extracellular vesicles are apoptotic bodies.

[0156] P71. The kit of any one of paragraphs P59 to P70, wherein the microplate comprises at least 24 wells.

[0157] P72. The kit of any one of paragraphs P59 to P71, wherein the microplate comprises at least 96 wells.

[0158] P73. The kit of any one of paragraphs P59 to P72, wherein the microplate comprises at least 384 wells.

[0159] General terminology and interpretation conventions Neither the claims nor any method described herein should be construed as requiring that steps be performed in a particular order, unless expressly recited, nor should the method be construed as supporting the performance of the recited steps in any order, unless expressly recited.

[0160] Certain features described in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable subcombination. Furthermore, although features may be described above as acting in a certain combination and even initially claimed as such, one or more features of the claimed combination may in some cases be deleted from the combination, and the claimed combination may be directed to a subcombination or a variation of the subcombination.

[0161] Articles such as "the," "a," and "an" may imply singular or plural, and the word "or" when used without the preceding "either" (or other similar words which clearly indicate that "or" is meant to be exclusive, such as only one of x or y), shall be construed as inclusive (e.g., "x or y" means either x or y, or both).

[0162] The term "and / or" is also to be construed as inclusive (e.g., "x and / or y" means either or both of x or y). In situations where "and / or" or "or" is used as a conjunction with a group of three or more items, the group should be construed to include one item alone, all items together, or any combination or number of items.

[0163] The terms have, having, include, and including should be construed as synonymous with the terms comprise and comprising, and the use of these terms should be understood as disclosing and supporting narrower alternative embodiments in which these terms are replaced with "consisting of" or "consisting essentially of."

[0164] Unless otherwise noted, all numbers or formulas used in this specification (other than the claims), e.g., expressing dimensions, physical characteristics, etc., are understood to be modified in each instance by the term "approximately." At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter recited in this specification or claims that is modified by the term "approximately" should be construed in light of the number of recited significant digits and by applying ordinary rounding techniques.

[0165] All ranges disclosed should be understood to include and support claims reciting any subranges or individual values ​​subsumed within each range. For example, the range 1-10 as specified should be considered to include and support claims reciting any subranges or individual values ​​between and / or including a minimum value of 1 and a maximum value of 10, i.e., all subranges beginning with a minimum value of 1 or more and ending with a maximum value of 10 or less (e.g., 5.5-10, 2.34-3.56, etc.), or any value between 1 and 10 (e.g., 3, 5.8, 9.9994, etc.), which may be expressed singly or as a minimum value (e.g., at least 5.8) or maximum value (e.g., less than or equal to 9.9994).

[0166] All numerical values ​​disclosed should be understood to range from 0 to 100% in either direction, and thus support a claim reciting such a value (either alone or as a minimum or maximum, e.g., at least <value> or not more than <value>), or any range or subrange that may be formed by such values. For example, the numerical value 8 as defined should be understood to range from 0 to 16 (100% in either direction), and support a claim reciting the range itself (e.g., 0 to 16), any subrange within that range (e.g., 2 to 12.5), or any individual value within that range expressed individually (e.g., 15.2) as a minimum (e.g., at least 4.3) or maximum (e.g., not more than 12.4).

[0167] Terms recited in the claims are to be given their ordinary and customary meanings, meanings commonly understood by a person skilled in the art, etc., as determined by reference to relevant entries in a commonly used general dictionary and / or relevant technical dictionary, with the understanding that the broadest meaning given by any one or combination of these sources is to be given to the claim terms (e.g., two or more relevant dictionary entries must be combined to result in the broadest meaning of the combination of entries), with the only exceptions being: (a) when a term is used in a manner broader than its ordinary and customary meaning, the term is to be given an additional broad meaning in addition to its ordinary and customary meaning, or (b) when a term is expressly defined to have a different meaning by reciting the term followed by the phrase "as used herein, shall mean," or similar language (e.g., "this term means," "this term is defined as," "for purposes of this disclosure, this term shall mean," etc.). Reference to specific examples, use of "i.e.," use of the word "invention," etc. are not intended to invoke exception (b) or to otherwise limit the scope of the recited claim terms. Other than in circumstances where exception (b) applies, nothing in this specification should be deemed a waiver or disclaimer of any claim.

[0168] Subject matter recited in the claims does not have, and should not be construed to have, the same scope as any embodiment, feature, or combination of features described or illustrated in this specification, even if only a single embodiment of a feature or combination of features is illustrated and described.

[0169] Incorporation by Reference The entire contents of each of the documents listed below are incorporated herein by reference. When the same term is used in both this specification and one or more of the incorporated documents, it should be interpreted as having the broadest meaning given by any one or combination of these sources, unless the term is expressly defined herein to have a different meaning. In the event of any inconsistency between any of the following documents and this specification, this specification shall prevail. The incorporated subject matter should not be used to limit or narrow the scope of the subject matter expressly listed or indicated.

[0170] - U.S. Patent No. 4,815,843, entitled "Optical Sensor for Selective Detection of Substances and / or for the Detection of Refractive Index Changes in Gaseous, Liquid, Solid and Porous Samples," filed May 29, 1986, and issued March 28, 1989 (Serial No. 07 / 019,557).

[0171] - U.S. Patent No. 5,738,825, entitled "Optical Biosensor Matrix," filed July 18, 1994 and issued April 14, 1998 (Serial No. 08 / 854,586).

[0172] -U.S. Patent No. 7,057,720, entitled "Optical Interrogation System and Method for Using Same," filed June 24, 2003 and issued June 6, 2006 (Serial No. 10 / 602,304).

[0173] -U.S. Patent No. 7,136,550, entitled "Single-Fiber Launch / Receive System for Biosensing Applications," filed October 28, 2004 and issued November 14, 2006 (Serial No. 10 / 977,520).

[0174] -U.S. Patent No. 7,203,386, entitled "Self-Referencing Waveguide Grating Sensors," filed September 21, 2004 and issued April 10, 2007 (Serial No. 10 / 947,021).

[0175] -U.S. Patent No. 7,239,395, entitled "Optical Interrogation Systems with Reduced Parasitic Reflections and a Method for Filtering Parasitic Reflections," filed May 27, 2004 and issued July 3, 2007 (serial number 10 / 856,572).

[0176] -U.S. Patent No. 7,286,221, entitled "Arrayed Sensor Measurement System and Method," filed December 21, 2004 and issued October 23, 2007 (Serial No. 11 / 019,439).

[0177] -U.S. Patent No. 7,292,333, entitled "Optical Interrogation System and Method for 2-D Sensor Arrays," filed April 5, 2005 and issued November 6, 2007 (Serial No. 11 / 100,199).

[0178] -U.S. Patent No. 7,346,233, entitled "Single Mode (SM) Fiber Optical Reader System and Method for Interrogating Resonant Waveguide-Grating Sensor(s)," filed February 14, 2005 and issued March 18, 2008 (Serial No. 11 / 058,155).

[0179] -U.S. Patent No. 7,604,984, entitled "Spatially Scanned Optical Reader System and Method for Using Same," filed December 29, 2004 and issued October 20, 2009 (Serial No. 11 / 027,547).

[0180] -U.S. Patent No. 8,114,348 (Serial No. 12 / 480,886), entitled "Label-Free High Throughput Biomolecular Screening System and Method," filed June 9, 2009 and issued February 14, 2012.

[0181] - U.S. Patent Application Publication No. 2006 / 0110594 (Serial No. 10 / 996,952), entitled "Polymer-Coated Substrates for Binding Biomolecules and Methods of Making and Using Thereof," filed November 24, 2004 and published May 25, 2006.

[0182] -U.S. Patent Application Publication No. 2006 / 0141527, filed December 29, 2004, and published June 29, 2006, entitled "Method for Creating a Reference Region and a Sample Region on a Biosensor and the Resulting Biosensor" (Serial No. 11 / 027,509).

[0183] Preferred embodiments of the present invention will be described below in detail.

[0184] EMBODIMENT 1 placing a sample containing extracellular vesicles on an optical waveguide biosensor; binding the extracellular vesicles to the optical waveguide biosensor; detecting the extracellular vesicles bound to the optical waveguide biosensor; analyzing a characteristic of the extracellular vesicles bound to the optical waveguide biosensor; A method comprising:

[0185] EMBODIMENT 2 2. The method of embodiment 1, wherein the characteristics of the extracellular vesicles include the number of extracellular vesicles in the sample, the size of the extracellular vesicles in the sample, and / or the type of extracellular vesicles in the sample.

[0186] EMBODIMENT 3 The method of embodiment 1, wherein analyzing the properties of the extracellular vesicles comprises binding a ligand to the extracellular vesicles.

[0187] EMBODIMENT 4 The method of embodiment 3, wherein the ligand comprises a first ligand that binds to a first marker on the extracellular vesicle and a second ligand that binds to a second marker on the extracellular vesicle.

[0188] EMBODIMENT 5 The method of embodiment 3, wherein the ligand comprises a label.

[0189] EMBODIMENT 6 2. The method of embodiment 1, wherein analyzing the characteristics of the extracellular vesicles comprises analyzing the intravesicular contents of the extracellular vesicles.

[0190] EMBODIMENT 7 The method of embodiment 6, wherein analyzing the intravesicular contents of the extracellular vesicles comprises analyzing proteins, RNA and / or DNA in the intravesicular contents.

[0191] EMBODIMENT 8 The method of embodiment 6, wherein analyzing the intravesicular contents of the extracellular vesicles comprises lysing the extracellular vesicles.

[0192] EMBODIMENT 9 2. The method of embodiment 1, wherein the sample is an unpurified biological sample.

[0193] EMBODIMENT 10 2. The method of embodiment 1, wherein the step of detecting the extracellular vesicles comprises illuminating the optical waveguide biosensor and detecting a change in the resonant wavelength of light reflected from the optical waveguide biosensor.

[0194] EMBODIMENT 11 2. The method of embodiment 1, wherein the optical waveguide biosensor is an optical resonant waveguide grating biosensor.

[0195] EMBODIMENT 12 A system for analyzing extracellular vesicles, comprising: an optical waveguide biosensor; an extracellular vesicle bound to the optical waveguide biosensor; A ligand containing a label bound to the extracellular vesicle. A system comprising:

[0196] EMBODIMENT 13 The system of embodiment 12, wherein the ligand is a first ligand, the label is a first label, and the system comprises a second ligand bound to the extracellular vesicle, the second ligand comprising a second label.

[0197] EMBODIMENT 14 The system of embodiment 13, wherein the first ligand is configured to bind to one marker on the extracellular vesicle and the second ligand is configured to bind to another marker on the extracellular vesicle.

[0198] EMBODIMENT 15 13. The system of embodiment 12, comprising an optical reader configured to detect the extracellular vesicles bound to the optical waveguide biosensor.

[0199] EMBODIMENT 16 A plurality of the optical waveguide biosensors; a microplate including a plurality of wells each including at least one of the plurality of optical waveguide biosensors; 13. The system of embodiment 12, comprising:

[0200] EMBODIMENT 17 A system for analyzing extracellular vesicles, comprising: a microplate containing a plurality of wells; an optical waveguide biosensor disposed in each of the plurality of wells; a sample disposed in each of said plurality of wells; Equipped with each of the samples comprising intravesicular contents of ruptured extracellular vesicles bound to the optical waveguide biosensor; system.

[0201] EMBODIMENT 18 18. The system of embodiment 17, wherein the sample comprises a lysis reagent.

[0202] EMBODIMENT 19 The system of embodiment 17, wherein the intravesicular contents of the ruptured extracellular vesicles comprise protein, RNA and / or DNA.

[0203] EMBODIMENT 20 A kit for analyzing extracellular vesicles, comprising: a microplate containing a plurality of wells; an optical waveguide biosensor disposed in each of the plurality of wells; a binding substance coupled to each of the optical waveguide biosensors and configured to bind to extracellular vesicles; (a) a ligand comprising a label, configured to bind to the extracellular vesicle; or (b) a reagent configured to rupture the extracellular vesicles. At least one of Including the kit.

[0204] EMBODIMENT 21 The kit of embodiment 20, wherein the ligand comprises a first ligand comprising a first label and a second ligand comprising a second label, the first ligand configured to bind to a first marker on the extracellular vesicle, and the second ligand configured to bind to a second marker on the extracellular vesicle.

[0205] EMBODIMENT 22 The kit of embodiment 20, comprising both (a) and (b).

Claims

1. placing a sample containing extracellular vesicles on an optical waveguide biosensor; binding the extracellular vesicles to the optical waveguide biosensor; detecting the extracellular vesicles bound to the optical waveguide biosensor; analyzing a characteristic of the extracellular vesicles bound to the optical waveguide biosensor; Including, the optical waveguide biosensor comprises a binding substance specific for a marker on the extracellular vesicles immobilized on its surface; the step of binding the extracellular vesicles to the optical waveguide biosensor comprises binding the extracellular vesicles to a surface of the optical waveguide biosensor using the binding agent; The method, wherein said optical waveguide biosensor is an optical resonant waveguide grating biosensor.

2. 2. The method of claim 1, wherein the characteristics of the extracellular vesicles include the number of extracellular vesicles in the sample, the size of the extracellular vesicles in the sample, and / or the type of extracellular vesicles in the sample.

3. Analyzing the properties of the extracellular vesicles includes binding a ligand to the extracellular vesicles; The ligand comprises a first ligand that binds to a first marker on the extracellular vesicle and a second ligand that binds to a second marker on the extracellular vesicle; the ligand comprises a label, or The method of claim 1 , comprising any combination thereof.

4. Analyzing the properties of the extracellular vesicles includes analyzing the intravesicular contents of the extracellular vesicles; Analyzing the intravesicular contents of the extracellular vesicles comprises analyzing proteins, RNA and / or DNA in the intravesicular contents; Analyzing the intravesicular contents of the extracellular vesicles comprises lysing the extracellular vesicles; or The method of claim 1 , comprising any combination thereof.

5. The method of claim 1 , wherein the sample is an unpurified biological sample.

6. 2. The method of claim 1, wherein the step of detecting extracellular vesicles comprises the steps of illuminating the optical waveguide biosensor and detecting a change in a resonant wavelength of light reflected from the optical waveguide biosensor.

7. A system for analyzing extracellular vesicles, comprising: an optical waveguide biosensor; an extracellular vesicle bound to the optical waveguide biosensor; and a ligand comprising a label, bound to the extracellular vesicle; the optical waveguide biosensor comprises an active surface on the optical waveguide biosensor for attaching and immobilizing a binding substance specific to a marker on the extracellular vesicles; the extracellular vesicles are bound to a surface of the optical waveguide biosensor using the binding agent; and The system, wherein the optical waveguide biosensor is an optical resonant waveguide grating biosensor.

8. the ligand is a first ligand and the label is a first label; the system comprising a second ligand bound to the extracellular vesicle, the second ligand comprising a second label; The first ligand is configured to bind to a marker on the extracellular vesicle; The system of claim 7 , wherein the second ligand is configured to bind to another marker on the extracellular vesicle.

9. The system of claim 7 , comprising an optical reader configured to detect the extracellular vesicles bound to the optical waveguide biosensor.

10. A plurality of the optical waveguide biosensors; a microplate including a plurality of wells each including at least one of the plurality of optical waveguide biosensors; The system of claim 7 , comprising:

11. A system for analyzing extracellular vesicles, comprising: a microplate containing a plurality of wells; an optical waveguide biosensor disposed in each of the plurality of wells; a sample disposed in each of the plurality of wells; each of the samples comprising intravesicular contents of ruptured extracellular vesicles bound to the optical waveguide biosensor; the optical waveguide biosensor comprises an active surface on the optical waveguide biosensor for attaching and immobilizing a binding substance specific to a marker on the extracellular vesicles; the extracellular vesicles are bound to a surface of the optical waveguide biosensor using the binding agent; and The system, wherein the optical waveguide biosensor is an optical resonant waveguide grating biosensor.

12. the sample contains a lysis reagent; the intravesicular contents of the ruptured extracellular vesicles comprise protein, RNA and / or DNA; or The system of claim 11 including any combination thereof.

13. A kit for analyzing extracellular vesicles, comprising: a microplate containing a plurality of wells; an optical waveguide biosensor disposed in each of the plurality of wells; a binding substance bound to each active surface of the optical waveguide biosensor, the binding substance being specific for a marker on the extracellular vesicles and configured to bind to the extracellular vesicles; (a) a ligand configured to bind to the extracellular vesicles, the ligand comprising a label; or (b) a reagent configured to rupture the extracellular vesicles. Including, The kit, wherein the optical waveguide biosensor is an optical resonant waveguide grating biosensor.

14. 14. The kit of claim 13, wherein the ligand comprises a first ligand comprising a first label and a second ligand comprising a second label, the first ligand configured to bind to a first marker on the extracellular vesicle and the second ligand configured to bind to a second marker on the extracellular vesicle.

Images